Causes and Consequences of Hypertriglyceridemia

Elevations in plasma triglyceride are the result of overproduction and impaired clearance of triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons. Hypertriglyceridemia is characterized by an accumulation in the circulation of large VLDL-VLDL1–and its lipolytic product...

Full description

Bibliographic Details
Main Authors: Chris J. Packard, Jan Boren, Marja-Riitta Taskinen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2020.00252/full
id doaj-4dd6d61a289d4b4a965634c23c05678e
record_format Article
spelling doaj-4dd6d61a289d4b4a965634c23c05678e2020-11-25T02:33:18ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-05-011110.3389/fendo.2020.00252532994Causes and Consequences of HypertriglyceridemiaChris J. Packard0Jan Boren1Marja-Riitta Taskinen2Institute of Cardiovascular and Medical Sciences, Glasgow University, Glasgow, United KingdomDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, SwedenResearch Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, FinlandElevations in plasma triglyceride are the result of overproduction and impaired clearance of triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons. Hypertriglyceridemia is characterized by an accumulation in the circulation of large VLDL-VLDL1–and its lipolytic products, and throughout the VLDL-LDL delipidation cascade perturbations occur that give rise to increased concentrations of remnant lipoproteins and small, dense low-density lipoprotein (LDL). The elevated risk of atherosclerotic cardiovascular disease in hypertriglyceridemia is believed to result from the exposure of the artery wall to these aberrant lipoprotein species. Key regulators of the metabolism of triglyceride-rich lipoproteins have been identified and a number of these are targets for pharmacological intervention. However, a clear picture is yet to emerge as to how to relate triglyceride lowering to reduced risk of atherosclerosis.https://www.frontiersin.org/article/10.3389/fendo.2020.00252/fulllipidmetabolismVLDLchylomicronapoB
collection DOAJ
language English
format Article
sources DOAJ
author Chris J. Packard
Jan Boren
Marja-Riitta Taskinen
spellingShingle Chris J. Packard
Jan Boren
Marja-Riitta Taskinen
Causes and Consequences of Hypertriglyceridemia
Frontiers in Endocrinology
lipid
metabolism
VLDL
chylomicron
apoB
author_facet Chris J. Packard
Jan Boren
Marja-Riitta Taskinen
author_sort Chris J. Packard
title Causes and Consequences of Hypertriglyceridemia
title_short Causes and Consequences of Hypertriglyceridemia
title_full Causes and Consequences of Hypertriglyceridemia
title_fullStr Causes and Consequences of Hypertriglyceridemia
title_full_unstemmed Causes and Consequences of Hypertriglyceridemia
title_sort causes and consequences of hypertriglyceridemia
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2020-05-01
description Elevations in plasma triglyceride are the result of overproduction and impaired clearance of triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons. Hypertriglyceridemia is characterized by an accumulation in the circulation of large VLDL-VLDL1–and its lipolytic products, and throughout the VLDL-LDL delipidation cascade perturbations occur that give rise to increased concentrations of remnant lipoproteins and small, dense low-density lipoprotein (LDL). The elevated risk of atherosclerotic cardiovascular disease in hypertriglyceridemia is believed to result from the exposure of the artery wall to these aberrant lipoprotein species. Key regulators of the metabolism of triglyceride-rich lipoproteins have been identified and a number of these are targets for pharmacological intervention. However, a clear picture is yet to emerge as to how to relate triglyceride lowering to reduced risk of atherosclerosis.
topic lipid
metabolism
VLDL
chylomicron
apoB
url https://www.frontiersin.org/article/10.3389/fendo.2020.00252/full
work_keys_str_mv AT chrisjpackard causesandconsequencesofhypertriglyceridemia
AT janboren causesandconsequencesofhypertriglyceridemia
AT marjariittataskinen causesandconsequencesofhypertriglyceridemia
_version_ 1724814930412044288